Caligan Partners’s Alimera Sciences ALIM Stock Holding History

Caligan Partners’s Portfolio ALIM Stock Details ALIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,835,154	Closed	-$93.6M	–	13
2024 Q2	$93.6M	Hold	16,835,154	–	–	21.87%	2
2024 Q1	$65.7M	Hold	16,835,154	–	–	17.36%	2
2023 Q4	$72.7M	Hold	16,835,154	–	–	24.53%	2
2023 Q3	$52.2M	Buy	16,835,154 +16,356,377	+3,416%	+$54.1M	23.97%	2
2023 Q2	$1.4M	Hold	478,777	–	–	0.79%	11
2023 Q1	$1.01M	Hold	478,777	–	–	0.7%	10
2022 Q4	$1.3M	Buy	+478,777	New	+$2.04M	1.08%	9

Caligan Partners's ALIM Position: Q3 2024 in Review

Caligan Partners sold out of Alimera Sciences (ALIM) in Q3 2024, closing a stake of 16,835,154 shares — an estimated $93.6M sold.

Caligan Partners first reported a position in ALIM in Q4 2022 and held it in 7 quarters. The position peaked at $93.6M in Q2 2024. 0 funds tracked by Wall St. Rank hold ALIM as of Q3 2024.

Caligan Partners reported no remaining Alimera Sciences position as of Q3 2024 after selling out during the quarter.
Caligan Partners sold 16,835,154 Alimera Sciences shares in Q3 2024, an estimated $93.6M.
Caligan Partners first reported a position in Alimera Sciences in Q4 2022 and held it in 7 quarters.
Caligan Partners's Alimera Sciences position peaked at $93.6M in Q2 2024.
0 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2024.

Based on Caligan Partners's 13F filing for Q3 2024, filed 14 Nov 2024.